Patrick Lamy - 07 May 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Reporting relationship: Senior VP, Commercial Strategy
Issuer ticker: AKRO
Reported as of: 07 May 2025
Net transaction value: -$180,990
SEC form: 4
Accepted by SEC: 09 May 2025, 19:18:09 UTC
Prior SEC filing: 05 Mar 2025
Next SEC filing: 23 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Young, Attorney-in-Fact

Key filing fact

Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 09 May 2025.

Key facts

This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 May 2025, 19:18.

Change

Previous filing in this sequence was filed on 05 Mar 2025.
Current net transaction value: -$180,990.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001961273 Primary reporting owner

Lamy Patrick

Relationship: Senior VP, Commercial Strategy
Address: C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO
Signature: /s/ Jonathan Young, Attorney-in-Fact
Signature date: 09 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKRO transaction

Common Stock

Options Exercise

Transaction value: $158,960
Shares: +8,000
Change %: +24%
Price: $19.87
Shares after: 41,492
Date: 07 May 2025
Ownership: Direct
Footnotes: F1

AKRO transaction

Common Stock

Sale

Transaction value: $198,895
Shares: -4,701
Change %: -11%
Price: $42.31
Shares after: 36,791
Date: 07 May 2025
Ownership: Direct
Footnotes: F1, F2

AKRO transaction

Common Stock

Sale

Transaction value: $141,055
Shares: -3,299
Change %: -9%
Price: $42.76
Shares after: 33,492
Date: 07 May 2025
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKRO transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -8,000
Change %: -10%
Price: $0.000000
Shares after: 70,182
Date: 07 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,000
Exercise price: $19.87
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 6, 2025, previously adopted by the Reporting Person.

Footnote F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.60 to $42.59, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.

Footnote F3

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.60 to $43.03, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.

Footnote F4

This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2023.